Clinical trials: Smoldering Myeloma
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g.…
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT05312255
- Testing
- Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma, Smoldering Multiple Myeloma
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or…
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Trial name
- NCT06768489
- Testing
- JNJ-79635322, Daratumumab, Pomalidomide
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 276 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Smoldering Myeloma
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors find better ways to ways to treat the cancer.
- Conditions
- Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT00919139
- Testing
- biologic sample preservation procedure
- Where
- 207 sites in United States
- Volunteers
- 190 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma, Smoldering, Multiple Myeloma
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks.
- Conditions
- Multiple Myeloma, Smoldering, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT06055894
- Testing
- Omega-3, Curcumin, Probiotic
- Where
- 7 sites in United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Smoldering Plasma Cell Myeloma
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma.
- Trial name
- NCT03631043
- Testing
- Biopsy Specimen Radiography, Lenalidomide, Vaccine Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Smoldering Multiple Myeloma
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM.
- Trial name
- ERASMM (NCT06183489)
- Testing
- Elranatamab
- Where
- 18 sites in France, Italy and 2 more
- Volunteers
- 50 people
- Sponsor
- European Myeloma Network B.V.
Smoldering Plasma Cell Myeloma
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
This phase II trial studies how well leflunomide works in treating patients with high-risk smoldering multiple myeloma. Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT03952832
- Testing
- Leflunomide, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- City of Hope Medical Center
Smouldering Myeloma
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patients who have intermediate or high risk smouldering myeloma.
- Trial name
- MODIFY (NCT06762769)
- Testing
- Isatuximab, Iberdomide, Dexamethasone
- Where
- 14 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- University College, London
Smoldering Plasma Cell Myeloma
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading.
- Trial name
- NCT02603887
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Smoldering Multiple Myeloma
Imaging Studies and the Development of Multiple Myeloma
Background: Multiple myeloma (MM) is a type of malignant blood cancer. It affects the plasma cells, which help produce antibodies and fight infection.
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT01571726
- Testing
- Fluciclatide
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Smoldering Multiple Myeloma
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma.
- Trial name
- NCT05767359
- Testing
- Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.
- Trial name
- REVIVE (NCT06100237)
- Testing
- Teclistamab, Talquetamab, Daratumumab SC
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Carl Ola Landgren, MD, PhD
Asymptomatic Multiple Myeloma
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma
The purpose of this study is to determine the safety and in vivo persistence and expansion of autologous and expansion of autologous, ex vivo expanded-natural killer(ENK) cells.
- Trial name
- NCT01884688
- Testing
- ENK Cell Infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Arkansas
Smoldering Multiple Myeloma
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk…
- Trial name
- NCT03301220
- Testing
- Daratumumab SC: daratumumab + rHuPH20
- Where
- 163 sites in United States, Argentina and 22 more
- Volunteers
- 390 people
- Sponsor
- Janssen Research & Development, LLC
Cancer Prevention, Weight Loss
PROFAST Intervention in Precursor Multiple Myeloma
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)…
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS
- Trial name
- PROFAST (NCT05565638)
- Testing
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
The purpose of this study is to determine if siltuximab has an effect on the heart function measured by ECG recordings and more specifically to determine if siltuximab has an effect on the QT interval in patients with Monoclonal…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT01219010
- Testing
- Siltuximab
- Where
- 8 sites in United States, Belgium and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Smoldering Multiple Myeloma
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56^dim cells (a marker for the health of the body's immune system)
- Trial name
- NCT01441973
- Testing
- Elotuzumab (BMS-901608; HuLuc63)
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Bristol-Myers Squibb
Smoldering Multiple Myeloma (SMM)
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing Multiple Myeloma (MM), a group commonly labeled as High-Risk Smoldering Multiple Myeloma (HR-SMM).
- Trial name
- NCT05955508
- Testing
- Linvoseltamab
- Where
- 17 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Amyloidosis
Registry for Adults With Plasma Cell Disorders (PCD's)
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric…
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
- Trial name
- NCT03717844
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Background: Multiple myeloma is a blood cancer that affects the plasma cells. These cells help produce antibodies and fight infection.
- Trial name
- NCT01572480
- Testing
- Carfilzomib, Revlimid, Dexamethasone
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)